In fact, Cetuximab, a monoclonal, anti-EGFR antibody that binds to EGFR and prevents activation of the downstream signaling pathway, was, until recently, the only approved targeted agent for HNSCC therapy. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.